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Hypertension, traditionally defined as a systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure 
(DBP) ≥90 mm Hg,1 and in 2017 redefined by the American 
Heart Association as an SBP ≥130 mm Hg or DBP ≥80 
mm Hg,2 is a highly prevalent condition which plays an essen-
tial role in the etiology of a wide range of cardiovascular dis-
eases. In 2011 to 2014, the prevalence of hypertension in adults 
in the United States, according to the most recent definition, 
was estimated at 45.6%.3 When left untreated, a high blood 
pressure can lead to adverse left ventricular (LV) remodeling, 
such as LV hypertrophy, which is associated with an increased 
incidence of heart failure and cardiovascular death.4–6 However, 
high blood pressure tends to cluster with other cardiovascular 
risk factors, such as obesity and smoking, making it difficult to 
identify independent effects of blood pressure on the structure 
and function of heart. Genome-wide association studies have 
successfully identified genetic variants associated with blood 
pressure and hypertension.7–12 Individuals with more blood 
pressure–raising alleles, and therefore, a higher genetic risk 
of developing hypertension, are at higher risk of developing 
coronary artery disease.13 It is yet unknown whether the re-
lationship between increased blood pressure and adverse LV 
remodeling is of a causal nature. This study aimed to assess 
the causality of previously established associations between 
increased blood pressure and adverse LV remodeling by deter-
mining the effect of genetically predicted SBP (gSBP) on LV 
structure and function.
Methods
The data for this study is publicly available to registered investi-
gators of the UK Biobank. Because of the sensitive nature of the 
data collected for this study, requests to access the dataset from 
qualified researchers trained in human subject confidentiality pro-
tocols may be sent to the UK Biobank at https://www.ukbiobank.
ac.uk/. Analyses were performed using individuals included in the 
cardiovascular magnetic resonance imaging (CMR) substudy of 
the UK Biobank resource14 with available short-axis cine images 
and genetic data (N=5596).15 Townsend deprivation index, an area-
based proxy for socioeconomic status, was calculated by the UK 
Biobank at baseline visit and inverse rank normalized. Body surface 
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Abstract—We aimed to estimate the effects of a lifelong exposure to high systolic blood pressure (SBP) on left ventricular 
(LV) structure and function using Mendelian randomization. A total of 5596 participants of the UK Biobank were included 
for whom cardiovascular magnetic resonance imaging and genetic data were available. Major exclusion criteria included 
nonwhite ethnicity, major cardiovascular disease, and body mass index >30 or <18.5 kg/m2. A genetic risk score to 
estimate genetically predicted SBP (gSBP) was constructed based on 107 previously established genetic variants. Manual 
cardiovascular magnetic resonance imaging postprocessing analyses were performed in 300 individuals at the extremes 
of gSBP (150 highest and lowest). Multivariable linear regression analyses of imaging biomarkers were performed using 
gSBP as continuous independent variable. All analyses except myocardial strain were validated using previously derived 
imaging parameters in 2530 subjects. The mean (SD) age of the study population was 62 (7) years, and 52% of subjects 
were female. Corrected for age, sex, and body surface area, each 10 mm Hg increase in gSBP was significantly (P<0.0056) 
associated with 4.01 g (SE, 1.28; P=0.002) increase in LV mass and with 2.80% (SE, 0.97; P=0.004) increase in LV 
global radial strain. In the validation cohort, after correction for age, sex, and body surface area, each 10 mm Hg increase 
in gSBP was associated with 5.27 g (SE, 1.50; P<0.001) increase in LV mass. Our study provides a novel line of evidence 
for a causal relationship between SBP and increased LV mass and with increased LV global radial strain.  (Hypertension. 
2019;74:826-832. DOI: 10.1161/HYPERTENSIONAHA.119.12679.) • Online Data Supplement
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area (BSA) was calculated as proposed by DuBois and DuBois.16 
Blood pressure was calculated as the mean value of 2 automated 
or manual measurements and was adjusted for the use of an auto-
mated device using a previously described algorithm.17 Physical ac-
tivity was calculated using answers from touchscreen questions and 
classified into moderate-intensity (3.0–6.0 metabolic equivalents) 
or vigorous-intensity physical activity (>6.0 metabolic equiva-
lents).18 Medical history was defined using self-reported answers 
from questionnaires and hospital episode statistics. Several diseases 
were additionally defined by medication use: hypertension (oral β 
blocker, ACE (angiotensin-converting enzyme) inhibitor, angio-
tensin II receptor antagonist, thiazide diuretic, and calcium channel 
blocker), hyperlipidemia (cholesterol-lowering medication), and 
diabetes mellitus (oral antidiabetic and insulin). Subjects with un-
available SBP measurements (n=40), unavailable height measure-
ments (n=6), nonwhite ethnicity (n=162), body mass index <18.5 
or >30 kg/m2 (n=1078), a medical history of coronary artery di-
sease, heart failure, cardiomyopathy, cardiac surgery, percutaneous 
cardiac intervention, peri-/myocarditis, cardiac arrhythmia, heart 
valve disease, pulmonary hypertension, use of oral anticoagulants, 
noncoronary arterial disease, stroke, thromboembolism, malig-
nancy, and renal failure (N=1101) were excluded from analyses. 
Nonwhite ethnicity (3% of the study population) was excluded 
to improve the homogeneity of the study population and because 
effects of genetic variants might vary across ethnicities. Subjects 
with major cardiovascular disease, active malignancy, renal failure, 
and obesity were excluded because their effect on LV structure and 
function has been reported and might dilute the observed effect of 
gSBP. After applying exclusion criteria, 3209 subjects remained in 
the study population.
Genotyping in the UK Biobank
The genotyping and imputation process in the UK Biobank has 
been described in more detail previously.15 Briefly, individuals were 
genotyped using either the custom UK Biobank Axiom array that in-
cluded 820 967 genetic variants (N=452 713; here N=2906) or the UK 
Biobank Lung Exome Variant Evaluation Axiom array that included 
807 411 genetic variants (N=49 949; here N=303). Both arrays have 
insertion and deletion markers and have >95% common content. UK 
Biobank provided imputed genotype data based on merged UK10K 
and 1000 Genomes phase 3 panels.
Mendelian Randomization
A genetic risk score (GRS) for SBP was constructed in all remaining 
participants to quantify gSBP using variants reported in literature. 
When this study was designed in June 2017, we identified 128 pre-
viously discovered genetic variants for SBP in previously reported 
genome-wide association studies,7–12 of which 126 were available 
in the UK Biobank, as listed in Table S1 in the online-only Data 
Supplement and described in Said et al.19 Because some studies re-
ported multiple correlated variants in the same genetic locus, the link-
age disequilibrium clumping procedure (at R2<0.01) implemented in 
PLINK version 1.9 was used to select 107 independent single nucleo-
tide polymorphisms (SNPS), based on the lowest reported P value. For 
these 107 genetic variants, we used reported effect sizes that were esti-
mated in the largest sample size that did not include UK Biobank data, 
for example, from the replication sample, to prevent circular inference 
and avoid overestimation of the effect. The GRS was constructed by 
summing the number of blood pressure–raising alleles (0, 1, or 2) for 
each individual after multiplying the alleles with the reported effect 
size of the genetic variant on SBP. Figure 1 highlights the association 
between gSBP and phenotypic SBP (pSBP). To optimize the statis-
tical power of the study, participants with the lowest and highest GRS 
values were selected for further CMR postprocessing analyses and 
were allocated to a low gSBP (N=150, 4.8% of study population) and 
high gSBP (N=150) group, respectively. Image quality was assessed 
by observers blinded to study group, based on presence of artifacts, 
axis alignment, and short-axis coverage of LV. In case of insufficient 
image quality (N=15), subjects were excluded from analyses and 
replaced by subjects with subsequent highest or lowest GRS values 
to keep 150 subjects in both groups. GRS thresholds used to select 
the final study groups were <4.45 mm Hg for the low gSBP group and 
>13.16 mm Hg for the high gSBP group (Figure 2).
CMR Postprocessing
Postprocessing analyses were performed by 2 experienced observers 
using cvi42 version 5.6.4 (Circle Cardiovascular Imaging, Calgary, 
Alberta, Canada), blinded to patient characteristics and study group. 
Epicardial and endocardial LV contours were traced at end-diastolic 
and end-systolic phases according to contemporary guidelines 
in short-axis cine series to determine LV mass, LV end-diastolic 
volume, and LV end-systolic volume.20 Papillary muscles and trabec-
ulae were included in the LV cavity. LV mass was determined at the 
end-diastolic phase. LV mass to volume ratio was calculated by di-
viding LV mass by LV end-diastolic volume. Myocardial strain mea-
surements were done using the cvi42 tissue tracking plugin (Figure 
S1). Peak global circumferential and radial strain were measured in 
the short-axis cine series. Peak global longitudinal strain was meas-
ured by manually tracing endocardial and epicardial contours at end-
diastolic phase in 3 long-axis cine series (2-chamber view, 3-chamber 
view, 4-chamber view) and calculating mean values. In case of insuf-
ficient quality of the 4-chamber view (N=9), 3-chamber view (N=6), 
or 2-chamber view (N=2) series due to severe artifacts or very poor 
axis alignment, measurements were excluded and mean values of the 
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Figure 1. Association between genetically predicted systolic blood 
pressure (gSBP) and phenotypic systolic blood pressure (pSBP). 
Presented is a local polynomial smooth plot with 95% CI, using the 
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Figure 2. Distribution of genetic risk score for systolic blood pressure 
in UK Biobank population after initial exclusion criteria (N=3209). gSBP 
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Validation cohort
To validate our results observed in a population with extreme GRS 
values, we used imaging parameters previously derived by Petersen et 
al,21,22 which were available in 2530 subjects out of 3209 subjects that 
remained in the study after applying inclusion and exclusion criteria 
and excluding our study population. LV myocardial strain measure-
ments were not available and could not be validated.
Statistical Analyses
Baseline characteristics of the study population are presented by 
study group. Continuous variables are presented as mean with SD 
when normally distributed and as median with interquartile range in 
case of a non-normal distribution. Categorical and dichotomous vari-
ables are presented as number with percentage. Differences between 
groups were compared using ANOVA for normally distributed con-
tinuous variables, Wilcoxon rank-sum for non-normally distributed 
continuous variables, and Pearson χ2 for categorical and dichotomous 
variables.
To determine intraobserver and interobserver variability in imag-
ing parameters, intraclass correlation coefficients for derived imag-
ing biomarkers were calculated in a subset of the study population in 
which postprocessing analyses were repeated. Linear regression anal-
yses were performed on derived imaging biomarkers using GRS (as 
an estimate of gSBP) as a continuous independent variable, adjusted 
for genotyping chip used and the first 5 principal components (to ad-
just for population structure). First, basic univariate linear regression 
analyses were performed. Next, multivariable linear regression analy-
ses were performed to correct for the effects of possible confounders, 
using 2 models of covariates. A basic model of covariates (model 1) 
included age and sex. In addition to age and sex, Model 2 also in-
cluded BSA, which is widely used for indexation of LV volumes, 
LV mass, and cardiac output, to reduce variation related to body 
size.21,23,24 The ratio between the variance of the imaging biomarker 
and the variance of pSBP explained by gSBP (R2) was determined 
using univariate linear regression analysis and reported. Interaction 
analyses were performed to test for the presence of interactions be-
tween gSBP, age, and sex, using model 2. Linear regression analyses 
were repeated in the validation cohort on all available imaging bio-
markers. To compare results of gSBP with effects of the phenotype, 
linear regression analyses were repeated using pSBP as a continuous 
independent variable. Unstandardized effect sizes on imaging bio-
markers were reported per 10 mm Hg gSBP and pSBP. A Bonferroni 
correction was applied to reduce the chance of type I error; a signifi-
cance level of 0.05/9=0.0056 was adopted as statistically significant. 
All aforementioned statistical analyses were conducted with STATA 
version 15.1 (StataCorp LP, College Station, TX).
Mendelian randomization assumes that (1) the instrumental vari-
able is associated with the risk factor of interest, (2) the instrumental 
variable is independent of confounders, and (3) the instrumental var-
iable does not affect the outcome except through the risk factor. The 
first assumption was assessed by linear regression of pSBP against 
gSBP. The second assumption was assessed by adding baseline char-
acteristics that were significantly different (P<0.05) between study 
groups (possible confounders) to linear regression analyses. The third 
assumption was assessed by including pSBP as a covariate to linear 
regression analyses with gSBP.
If a significant effect of gSBP on a specific imaging parameter 
was observed after multivariable adjustment with model 2, statistical 
tests were performed to assess the presence of pleiotropy or hetero-
geneity of the observed effect estimates. Individual SNP effect sizes 
on SBP were determined in all UK Biobank participants with availa-
ble genetic information and no CMR assessment performed, using the 
same cutoff values for GRS as the study population (<4.45 and >13.16 
mm Hg). Individual SNP effect sizes on imaging parameters were 
determined using linear regression, corrected for confounders using 
model 2, and visualized using Forest plots and scatter plots. Results 
from inverse-variance–weighted fixed-effects meta-analyses of effect 
size on imaging parameters were reported. Mendelian randomization–
Egger intercepts were determined; a P<0.10 was considered evidence 
for pleiotropic bias. A Cochran Q test was performed; a heterogeneity 
P<0.05 was considered evidence for heterogeneity. Heterogeneity and 
pleiotropy tests were performed using the MR Base package (https://
mrcieu.github.io/TwoSampleMR/) in R version 3.3.2.
Results
Population Characteristics
Baseline characteristics of the study population are presented 
in Table 1. The mean (SD) age of the study population was 62 
(7) years, and 52% of subjects were female. The difference 
in median gSBP between study groups was 10.34 mm Hg, 
whereas the difference in mean pSBP between groups was 
7.56 mm Hg. The observed difference in mean pSBP was 
largely due to a difference in pulse pressure of 5.11 mm Hg 
and to a lesser extent due to a difference in DBP of 2.45 
mm Hg. The overlap in pSBP between study groups is dis-
played in Figure 3. In the high gSBP group, 47 subjects (31%) 
were diagnosed with hypertension, of which 41 (27%) used 
antihypertensive medication. In the low gSBP group, 26 sub-
jects (17%) were diagnosed with hypertension, of which 18 
(12%) used antihypertensive medication. Other significant 
baseline differences between groups not directly related to 
blood pressure were Townsend deprivation index (P=0.010), 
hours of moderate physical activity per week (P=0.033), and 
smoking status (P=0.008).
Mendelian Randomization: Effect of gSBP on LV 
Structure and Function
Interobserver and intraobserver variability in determining im-
aging parameters was above 0.90 in all investigated param-
eters except LV mass to volume ratio and LV ejection fraction 
(Table S2). Results from regression analyses with gSBP are 
presented in Table 2. We observed a significant (P<0.0056) 
association between gSBP and LV mass and LV global radial 
strain. Corrected for age, sex, and BSA, each 10 mm Hg in-
crease in gSBP was associated with 4.01 g (SE, 1.28; P=0.002) 
increase in LV mass and with 2.80% (SE, 0.97; P=0.004) in-
crease in LV global radial strain.
Mendelian Randomization: Testing Assumptions
In our study population (N=300), gSBP was significantly as-
sociated with pSBP (P<0.001) and explained 5.5% of its var-
iance. Adding baseline characteristics that were significantly 
different (P<0.05) between study groups (Townsend depri-
vation index, moderate physical activity, smoking status) to 
linear regression analyses did not change the observed effect 
of gSBP on LV mass and global radial strain from significant 
to nonsignificant. Adding pSBP to linear regression analyses 
changed the associations between gSBP and both LV mass 
and LV global radial strain from significant to nonsignificant 
(P=0.10 and P=0.030, respectively).
Mendelian Randomization: Pleiotropy and 
Heterogeneity
Pleiotropy and heterogeneity analyses were performed for 
observed associations between gSBP and LV mass and LV 
peak global radial strain. Forest plots and scatter plots with 
meta-analyzed results are presented in Figure S2 and Figure 
S3, respectively. Results from inverse-variance–weighted 
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intercepts and heterogeneity P values from Cochran Q test are 
presented in Table S3. There was no evidence for pleiotropic 
bias or heterogeneity in any of the investigated associations.
Interactions Between gSBP, Age and Sex
There was a significant interaction between gSBP and age on LV 
global radial strain (P=0.031), suggesting a difference in effect 
of gSBP on radial strain with varying age. An additional inter-
action was observed between gSBP and sex on LV end-systolic 
volume (P=0.030), suggesting a reduction of LV end-systolic 
volume with increasing gSBP in males, but not in females.
Validation Using Previously Derived Imaging 
Parameters
We attempted to validate the observed results by repeating linear re-
gression analyses with gSBP on LV mass, volumes, mass to volume 
ratio, cardiac output, and ejection fraction in 2530 independent 
subjects with previously derived imaging parameters (Table 3). As 
in the study cohort, we observed a significant (P<0.0056) associa-
tion between gSBP and LV mass in the validation cohort; all other 
associations were nonsignificant. Corrected for age, sex, and BSA, 
a 10 mm Hg increase in gSBP was associated with an increase of 
5.27 g (SE, 1.50; P<0.001) in LV mass. The interaction between 
gSBP and sex on LV end-systolic volume could not be reproduced 
in the validation cohort (P>0.05). LV myocardial strain measures 
were not available in the validation cohort.
Discrepancies With Phenotype Associations
Results from regression analyses of pSBP are reported in 
Table S4. Corrected for age, sex, and BSA, we observed sig-
nificant associations (P<0.0056) between pSBP and LV mass 
(β, 2.87±0.46 g/10 mm Hg; P<0.001) and LV global radial 
strain (β, 1.07±0.37 %/10 mm Hg; P=0.004). Associations 
that were significant for the phenotype but not for the geno-
type were associations between pSBP and LV mass to volume 
ratio (β, 0.0138±0.0032 /10 mm Hg; P<0.001) and cardiac 
output (β, 0.20±0.04 L/10 mm Hg; P<0.001).
Discussion
We investigated CMR-derived measures of LV structure and 
function in 300 individuals with extremes of gSBP. The main 
findings of our study were observed associations between 
gSBP and increased LV mass and LV global radial strain, pro-
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Figure 3. Distribution of systolic blood pressure at imaging visit per study 
group. gSBP indicates genetically predicted systolic blood pressure.






Genetic risk score for 
systolic blood pressure, 
mm Hg
3.52 (2.85–4.10) 13.86 (13.43–14.45) <0.001
Age, y 61.31 (7.54) 62.13 (6.98) 0.33
Sex (male) 76 (50.7%) 69 (46.0%) 0.42
Townsend deprivation 
index at recruitment, 
inverse rank normalized
0.02 (0.94) −0.27 (0.99) 0.010
Average total household income before tax, visit 2
  <18 000 27 (19.6%) 13 (9.2%) 0.13
  18 000–30 999 36 (26.1%) 37 (26.2%)
  31 000–51 999 32 (23.2%) 42 (29.8%)
  52 000–100 000 34 (24.6%) 36 (25.5%)
  >100 000 9 (6.5%) 13 (9.2%)
Weight, kg 72.30 (10.96) 71.83 (10.81) 0.71
Height, cm 169.26 (8.77) 169.13 (8.82) 0.89
Body mass index, kg/m2 25.15 (2.64) 25.04 (2.68) 0.71
Body surface area, m2 1.83 (0.17) 1.82 (0.17) 0.76
Waist hip ratio 0.85 (0.08) 0.84 (0.07) 0.27
Systolic blood pressure, 
mm Hg
125.09 (16.57) 132.65 (15.94) <0.001
Diastolic blood 
pressure, mm Hg
76.83 (8.15) 79.28 (8.12) 0.009
Pulse pressure, mm Hg 48.26 (11.90) 53.37 (12.20) <0.001
Mean arterial pressure, 
mm Hg
92.92 (10.22) 97.07 (9.78) <0.001
Total moderate physical 
activity, h/wk
6.35 (3.08–14.38) 9.33 (3.71–16.05) 0.033
Total vigorous physical 
activity, h/wk
1.38 (0.19–3.50) 1.44 (0.38–3.42) 0.33
Smoking behavior
  Nonsmoker 78 (52.0%) 105 (70.0%) 0.008
  Past smoker 62 (41.3%) 42 (28.0%)
  Active, occasional 
smoker
5 (3.3%) 2 (1.3%)
  Active, daily smoker 5 (3.3%) 1 (0.7%)
Alcohol intake, UK 
Units/wk
9.60 (3.20–16.10) 9.60 (3.20–18.80) 0.88
Hypertension 26 (17.3%) 47 (31.3%) 0.005
Antihypertensive 
medication use
18 (12.0%) 41 (27.3%) <0.001
Diabetes mellitus 5 (3.3%) 11 (7.3%) 0.12
Hyperlipidemia 27 (18.0%) 37 (24.7%) 0.16
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Hypertension does generally not lead to symptoms,6 
meaning that individuals who are affected often do not visit 
a medical professional until a symptomatic comorbidity, 
such as myocardial ischemia due to coronary artery disease, 
has manifested. Hypertension is the leading risk factor for 
deaths caused by cardiovascular diseases, causing >40% of 
cardiovascular deaths.25 Even small increases in blood pres-
sure from thresholds of 115 mm Hg SBP and 75 mm Hg DBP 
have been associated with an increased risk of cardiovas-
cular events.26 Therefore, more recently, the American Heart 
Association’s 2017 guideline has suggested lower thresholds 
for stage 1 hypertension at SBP values between 130 and 139 
mm Hg and DBP values between 80 and 89 mm Hg.2 The as-
sociation between raised SBP and increased risk of cardio-
vascular disease has been shown repeatedly,1,2 resulting in its 
inclusion in commonly used prediction models, such as the 
Framingham risk score.27
Magnetic resonance analyses using GRSs can provide 
evidence for causal relationships. This is especially valu-
able in studying processes with a multifactorial cause such 
as LV remodeling. gSBP has been previously associated with 
increased risk of cardiovascular diseases, such as coronary 
heart disease, atrial fibrillation, and stroke.10,13,28 To our know-
ledge, the present study is the first to report the association 
between gSBP and changes in CMR-derived measurements 
of LV structure and function. The current study provides evi-
dence for a causal relationship between SBP and adverse LV 
remodeling. We observed a large effect of gSBP on LV mass. 
These findings are in line with an earlier study that showed a 
significant association between gSBP using 29 genetic vari-
ants and increased LV wall thickness as measured by echocar-
diography.29 Similar associations for pSBP have been reported 
before.30 LV mass and concentricity are known to be strong 
predictors of incident cardiovascular events.31 Although CIs 
somewhat overlapped, point estimates of the effect size of 
gSBP were larger compared with pSBP. The observed effect 
sizes are likely underestimated because the GRS for SBP was 
based on the estimated effect size of SBP-raising genetic vari-
ants, and differences in GRS between groups were larger than 
differences in measured SBP. Larger effects of gSBP on LV 
mass compared with pSBP is an expected result, as pSBP is a 
snapshot at a specific moment in time, affected by many con-
founding factors (such as white coat hypertension), whereas 
gSBP is stable and its effects are cumulative over a whole 
lifetime.
We observed a strong association between gSBP and 
increased LV radial strain, which was also observed for pSBP, 
but to a much lesser extent. Previous studies have mostly re-
ported associations between hypertension and impaired LV lon-
gitudinal strain and in some cases also impaired circumferential 
Table 2. Linear Regression Analyses of gSBP on Imaging Biomarkers (N=300)
Imaging Biomarker
Univariate Model 1 Model 2
R2/R2
SBP
β±SE P Value β±SE P Value β±SE P Value
LV mass (g) 2.90±2.01 0.15 4.37±1.40 0.002 4.01±1.28 0.002 0.16
LV end-diastolic volume (mL) 0.10±3.59 0.98 2.74±2.82 0.33 2.05±2.62 0.44 0.00
LV end-systolic volume (mL) −1.47±2.06 0.47 −0.10±1.70 0.95 −0.36±1.66 0.83 0.03
LV mass to end-diastolic volume ratio 0.0177±0.0094 0.060 0.0194±0.0087 0.025 0.0191±0.0087 0.028 0.27
LV cardiac output (L/min) 0.04±0.13 0.78 0.12±0.11 0.29 0.10±0.11 0.37 0.01
LV ejection fraction (%) 1.00±0.66 0.13 0.81±0.64 0.21 0.79±0.65 0.22 0.14
LV peak global circumferential strain (%) −0.79±0.28 0.005 −0.66±0.27 0.014 −0.66±0.27 0.014 0.49
LV peak global radial strain (%) 3.24±1.02 0.002 2.80±0.97 0.004 2.81±0.97 0.004 0.62
LV peak global longitudinal strain (%) −0.03±0.25 0.91 −0.06±0.25 0.80 −0.06±0.25 0.82 0.00
Reported are unstandardized coefficients and SEs per 10 mm Hg increase of gSBP (genetic risk score). Model 1 consists of covariates age and sex. Model 2 consists 
of covariates age, sex, and body surface area. All analyses are adjusted for the genotyping chip used and the first 5 principal components. gSBP indicates genetically 
predicted SBP; LV, left ventricular; and SBP, systolic blood pressure.
Table 3. Replication of gSBP Effect Size in Previously Determined Imaging Biomarkers by Petersen et al21,22 (N=2530)
Imaging Biomarker
Univariate Model 1 Model 2
R2/R2
SBP
β±SE P Value β±SE P Value β±SE P Value
LV mass, g 7.14±2.25 0.001 5.90±1.63 <0.001 5.27±1.50 <0.001 0.29
LV end-diastolic volume, mL 7.54±3.23 0.020 5.75±2.56 0.025 4.82±2.38 0.043 0.15
LV end-systolic volume, mL 4.75±1.82 0.009 3.84±1.54 0.013 3.42±1.48 0.021 0.18
LV mass to end-diastolic volume ratio 0.0157±0.0110 0.15 0.0146±0.0105 0.16 0.0140±0.0105 0.18 0.06
LV cardiac output, L/min 0.11±0.11 0.34 0.07±0.10 0.47 0.04±0.10 0.66 0.03
LV ejection fraction, % −0.70±0.59 0.24 −0.59±0.58 0.31 −0.57±0.58 0.33 0.03
Reported are unstandardized coefficients and SEs per 10 mm Hg increase of gSBP (genetic risk score). Model 1 consists of covariates age and sex. Model 2 consists 
of covariates age, sex, and body surface area. All analyses are adjusted for the genotyping chip used and the first 5 principal components. gSBP indicates genetically 
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strain.32,33 Other studies observed that LV myocardial strain is 
most significantly impaired in subjects with both obesity and hy-
pertension,34 and we investigated a population free of obesity. 
As a prolonged exposure to high blood pressure can eventually 
progress into heart failure, we suspect that these studies have 
investigated individuals that had already suffered hypertension-
related injury to the myocardium. We hypothesize that in a ge-
neral population, blood pressure is associated with increased 
LV contractility and myocardial strain, whereas in more severe 
stages of hypertension, it is associated with strain impairment.
Future Perspectives
Our study indicates that gSBP is strongly related to increased 
LV mass, and radial strain indicating that long-term exposure 
to higher blood pressure directly impacts cardiac structure and 
function. Future studies will have to reveal whether a geneti-
cally predicted risk of hypertension also has additional value in 
predicting and preventing cardiovascular risk. GRSs are a po-
tential detection tool that can be used for the prevention of car-
diovascular disease, starting from an early stage in life. Because 
genetic variants are present from conception, they will have a 
cumulative burden on the cardiovascular system during one’s 
lifetime. However, not only genetic composition but also life-
style is strongly associated with risk of developing hypertension 
and future (cardiovascular) events.19 The effect of lifestyle on 
cardiovascular disease, as well as the effect of lifestyle on pSBP 
are independent from the effects of gSBP.19,35 Risk stratification 
based on genetic composition as well as lifestyle might even-
tually lead to clinical trial designs where individuals at high 
genetic risk receive early antihypertensive lifestyle or pharma-
cological interventions. Future studies could aim at determining 
whether hypertensive individuals with a large genetic compo-
nent respond differently to pharmacological treatment.
Strengths and Limitations
This study is the first to perform Mendelian randomization 
analyses of SBP on CMR-derived imaging biomarkers of LV 
structure and function. Major strengths of this study were the 
use of CMR data, balanced GRS-based groups, and the com-
parison between genotype and phenotype.
A limitation of our study that should be considered is that 
we investigated subjects with extreme GRS values and, there-
fore, did not cover the full range as is usually done in magnetic 
resonance analyses. We were, however, able to validate some 
of our results in a large subset of UK Biobank participants 
with previously derived imaging parameters and a normal dis-
tribution of genetic risk. A second limitation is that we have 
selected a relatively healthy population, free of obesity, and 
therefore, our results might not be generalizable.
Perspectives
By investigating associations between genetically predicted 
higher SBP and imaging parameters derived from CMR, our 
study provides evidence supporting a causal relationship be-
tween SBP and increased LV mass and increased LV global 
radial strain. These results further improve our understanding 
of pathophysiology in hypertensive heart disease. As more ge-
netic variants related to blood pressure are being discovered, 
genetic variants more strongly associated with adverse cardiac 
remodeling, such as concentric hypertrophy, could provide 
potential targets for therapy.
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What Is New?
•	Mendelian randomization analyses of systolic blood pressure on cardi-
ovascular magnetic resonance imaging–derived biomarkers of left ven-
tricular structure and function, and comparisons with the phenotype.
•	Genetically predicted systolic blood pressure was associated with in-
creased left ventricular mass and left ventricular global radial strain.
What is Relevant?
•	Evidence for causal links between systolic blood pressure and increased 
left ventricular mass and increased left ventricular global radial strain.
Summary
Performing a Mendelian randomization analysis of systolic blood 
pressure on imaging biomarkers of left ventricular structure and 
function resulted in evidence for causal links between systolic 
blood pressure and increased left ventricular mass and increased 
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